Raymond James & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-30,808
| Closed | -$5.66M | – | 4328 |
|
|
2021
Q2 | $5.66M | Sell |
30,808
-4,018
| -12% | -$690K | 0.01% | 1410 |
|
|
2021
Q1 | $5.33M | Sell |
34,826
-194,357
| -85% | -$30.1M | 0.01% | 1390 |
|
|
2020
Q4 | $35.8M | Sell |
229,183
-25,797
| -10% | -$3.31M | 0.04% | 398 |
|
|
2020
Q3 | $29.2M | Buy |
254,980
+12,085
| +5% | +$1.3M | 0.04% | 411 |
|
|
2020
Q2 | $27.3M | Sell |
242,895
-6,725
| -3% | -$714K | 0.04% | 404 |
|
|
2020
Q1 | $22.4M | Sell |
249,620
-4,366
| -2% | -$428K | 0.04% | 417 |
|
|
2019
Q4 | $27.5M | Buy |
253,986
+24,485
| +11% | +$2.62M | 0.03% | 443 |
|
|
2019
Q3 | $22.5M | Sell |
229,501
-47,805
| -17% | -$5.39M | 0.03% | 502 |
|
|
2019
Q2 | $36.3M | Sell |
277,306
-16,939
| -6% | -$2.18M | 0.05% | 336 |
|
|
2019
Q1 | $39.8M | Buy |
294,245
+30,991
| +12% | +$3.85M | 0.06% | 301 |
|
|
2018
Q4 | $25.6M | Sell |
263,254
-23,615
| -8% | -$2.79M | 0.04% | 378 |
|
|
2018
Q3 | $39.9M | Buy |
286,869
+49,770
| +21% | +$6.24M | 0.06% | 290 |
|
|
2018
Q2 | $29.4M | Buy |
237,099
+36,119
| +18% | +$4.22M | 0.05% | 364 |
|
|
2018
Q1 | $22.4M | Buy |
200,980
+17,403
| +9% | +$2.08M | 0.04% | 426 |
|
|
2017
Q4 | $22M | Sell |
183,577
-2,327
| -1% | -$283K | 0.04% | 432 |
|
|
2017
Q3 | $26.1M | Buy |
185,904
+62,979
| +51% | +$8.56M | 0.05% | 353 |
|
|
2017
Q2 | $15M | Sell |
122,925
-25,065
| -17% | -$2.92M | 0.03% | 542 |
|
|
2017
Q1 | $17.9M | Sell |
147,990
-20,477
| -12% | -$2.64M | 0.04% | 434 |
|
|
2016
Q4 | $20.6M | Sell |
168,467
-37,407
| -18% | -$4.58M | 0.05% | 355 |
|
|
2016
Q3 | $25.2M | Sell |
205,874
-1,047
| -0.5% | -$135K | 0.07% | 278 |
|
|
2016
Q2 | $24.2M | Buy |
206,921
+25,573
| +14% | +$3.63M | 0.08% | 271 |
|
|
2016
Q1 | $25.2M | Buy |
181,348
+34,499
| +23% | +$5.07M | 0.09% | 248 |
|
|
2015
Q4 | $28M | Buy |
146,849
+54,145
| +58% | +$9.46M | 0.1% | 218 |
|
|
2015
Q3 | $14.5M | Buy |
92,704
+18,121
| +24% | +$3.31M | 0.06% | 352 |
|
|
2015
Q2 | $13.5M | Buy |
74,583
+12,174
| +20% | +$2.1M | 0.05% | 417 |
|
|
2015
Q1 | $10.8M | Buy |
62,409
+2,456
| +4% | +$445K | 0.05% | 419 |
|
|
2014
Q4 | $11.1M | Buy |
59,953
+5,279
| +10% | +$978K | 0.05% | 376 |
|
|
2014
Q3 | $9.07M | Buy |
54,674
+4,540
| +9% | +$746K | 0.05% | 390 |
|
|
2014
Q2 | $7.83M | Buy |
50,134
+2,222
| +5% | +$351K | 0.05% | 439 |
|
|
2014
Q1 | $7.29M | Sell |
47,912
-7,961
| -14% | -$1.27M | 0.05% | 431 |
|
|
2013
Q4 | $7.42M | Buy |
55,873
+1,344
| +2% | +$161K | 0.06% | 392 |
|
|
2013
Q3 | $6.33M | Buy |
54,529
+1,646
| +3% | +$181K | 0.05% | 387 |
|
|
2013
Q2 | $4.88M | Buy |
+52,883
| New | +$5.1M | 0.05% | 436 |
|
Other funds holding ALXN
BCI
NICM
TAIM
RG
CFO
MAM